Navigation Links
Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer,Study Presented at ASCO

Of the ten patients evaluated, all ten patients completed four weeks, while seven of the ten patients completed eight weeks of therapy. Among the ten evaluable patients, there was one complete response (CR), one partial response (PR), and one patient with a 30% reduction in tumor volume.

Patients also underwent sequential biopsies of their tumors to evaluate biomarkers of hypoxia and angiogenesis. Paclitaxel causes an increase in tumor HIF-1alpha expression, which is downregulated by 2ME2. Changes were observed in HIF-1 regulated proteins, including tissue VEGF, VEGFR-2, plasma PAI-1, and osteopontin. Based on these findings, enrollment is continuing to further define the relationship between 2ME2 therapy and the effects on these biomarkers with the goal of identifying patients who would most benefit from 2ME2's unique mechanisms of action.

Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented on the study, "Results to date are encouraging and further support EntreMed's rationale for using Panzem(R) NCD in combination with approved chemotherapeutics. Panzem(R) NCD's safety profile and lack of MDR chemoresistance offer opportunities for combining it with conventional chemotherapies to increase their effectiveness without increasing toxicity."

Dr. Sidor further commented, "Breast cancer remains a significant health problem, killing over 40,000 American women annually, despite the introduction of new therapies. A primary resistance mechanism to chemotherapeutic agents is thought to be the upregulation of HIF-1alpha and Panzem(R) is a potent inhibitor of HIF-1alpha. We hope that this study will also begin to identify biomarkers that we can use to further identify patients who would most benefit from treatment with Panzem(R) NCD."

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:8/26/2014)... 2014  Kewaunee Scientific Corporation (Nasdaq: KEQU ... July 31, 2014. Sales for the quarter ... the first quarter last year. Net earnings for the ... compared to net earnings of $1,587,000, or $0.61 per ... year. However, both sales and earnings in the first ...
(Date:8/26/2014)... YORK , Aug. 26, 2014 /PRNewswire/ ... research report is available in its catalogue: ... Outlook to 2020 ... Gastroscopes Market Outlook to 2020 Summary ... Gastroscopes Market Outlook to 2020", provides key ...
(Date:8/26/2014)... Del. , Aug. 26, 2014 Biomedical ... it has been named to the prestigious 2014 Inc. ... are honored to be included on this prestigious list ... said Chris Jacob , Biomedical Research Laboratories, CEO. ... and further serves to validate the hard work and ...
Breaking Medicine Technology:Kewaunee Scientific Reports Results for First Quarter 2Kewaunee Scientific Reports Results for First Quarter 3Kewaunee Scientific Reports Results for First Quarter 4Kewaunee Scientific Reports Results for First Quarter 5Kewaunee Scientific Reports Results for First Quarter 6Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 2Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 3Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 4Japan Esophagoscopes & Gastroscopes Market Outlook to 2020 5Biomedical Research Laboratories Named to Inc. 500 List of America's Fastest-Growing Companies 2
(Date:8/27/2014)... chemicals, which repel water and oil and are ... industrial processing. These characteristics have made the fluorochemicals ... coatings for food paper and board. , The ... to break down and accumulate in both humans ... with harmful health effects, such as cancer, increased ...
(Date:8/27/2014)... When a friend invited Misty Mozejko to join ... was the beginning of a new way of life and a ... Misty. “I knew I needed to turn my life around but ... been, Misty stuck with the program. “It was so difficult,” she ... of my comfort zone, but between the boot camp and some ...
(Date:8/27/2014)... 27, 2014 According to market research ... Servo), Power Range (Micro, Low, Medium, High), Voltage (Low ... and Geography - Global Market Trends & Forecast to ... market with an analysis and forecast of the market ... an estimated $16.64 billion in 2014 to $22.73 billion ...
(Date:8/27/2014)... 27, 2014 Humility of Mary Health ... St. Elizabeth Boardman Health Center in Boardman beginning Sept. ... Niles beginning Sept. 8. , SlimDown teaches participants to ... to food, physical activity and behavior. , Classes run ... Boardman Health Center and Mondays at St. Joe’s at ...
(Date:8/27/2014)... Ellen V. Krieger, DDS released a new video describing her ... to describe the business and industry best practices for ... of cosmetic and family dentistry experience, Dr Ellen Krieger is ... and cared for. , Dr. Krieger has practiced dentistry in ... solid reputation of offering bright, friendly service to all of ...
Breaking Medicine News(10 mins):Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 2Health News:Leading scientists call for a stop to non-essential use of fluorochemicals 3Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Variable Frequency Drives Market Worth $22.73 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Humility of Mary Health Partners Offers SlimDown Classes 2Health News:Ellen V. Krieger, DDS of McLean, Virginia Announces New Video Describing Industry Best Practices 2
... MYL ),today announced that in accordance with its 2.139 ... dividend of $16.25 per,share (based on the annual dividend ... share) payable on May 15, 2008, to holders of,preferred ... Mylan Inc., with operations in more than 90 countries, ...
... "Cover the Uninsured Week," an,annual campaign that ... million,Americans who live without health insurance., ... PFE ) at:, http://media.medialink.com/WebNR.aspx?story=35042 , ... graphics and,photos for free and unrestricted use ...
... /PRNewswire-FirstCall/ - SXC Health Solutions,Corp. ("SXC" or the "Company") ... indirect, wholly-owned subsidiary has accepted for payment and,exchange all ... all,outstanding shares of common stock of National Medical Health ... share price of $7.70 in cash, without,interest, and 0.217 ...
... Say McCain Health Plan Dismantles Employer-based Health Care, ... Negative Impact, WASHINGTON, April 29 Sen. ... system that covers,more than 60 percent of non-elderly ... experts responding to the announcement of his proposal,today. ...
... dropout rate, study says , , TUESDAY, April 29 (HealthDay ... those not currently injecting drugs, are most likely to ... , University of Kent and Kings College London researchers ... programs and found that 25 percent left the programs ...
... treatments, two studies suggest , , TUESDAY, April 29 (HealthDay ... of gene variants linked to bone density and the risk ... While not a predictor of individual risk for osteoporosis, this ... they noted. , "When we look at a screening of ...
Cached Medicine News:Health News:SXC Health Solutions announces completion of exchange offer for NMHC 2Health News:SXC Health Solutions announces completion of exchange offer for NMHC 3Health News:SXC Health Solutions announces completion of exchange offer for NMHC 4Health News:McCain Would Drive Up Health Care Costs for Families, While Benefiting Health Insurance Companies 2Health News:McCain Would Drive Up Health Care Costs for Families, While Benefiting Health Insurance Companies 3Health News:Youngest Drug Users Most Likely to Leave Treatment Programs 2Health News:Genes Linked to Osteoporosis Identified 2Health News:Genes Linked to Osteoporosis Identified 3
... Single PCMCIA card provides diagnostic ... Burdicks SpiroCard is on a PCMCIA ... portable package. SpiroCard card,is full-featured and ... conventional,instrument. The device interfaces to Office,Medic ...
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
Incontinence Pessaries...
The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
Medicine Products: